Treatment of alopecia areata partim universalis with efalizumab

Kaelin, Ursula; Hassan, Akmhal Said; Braathen, Lasser Roger; Yawalkar, Nikil (2006). Treatment of alopecia areata partim universalis with efalizumab. Journal of the American Academy of Dermatology, 55(3), pp. 529-32. New York, N.Y.: Elsevier 10.1016/j.jaad.2006.05.062

Full text not available from this repository. (Request a copy)

Alopecia areata (AA) is considered an autoimmune disease targeted at hair follicles with T-lymphocytes playing an important role in the pathogenesis. Treatment of AA, particularly the totalis and universalis subtypes, is often difficult and remains a therapeutic challenge. Novel biologic therapies that have been developed for the treatment of other immune-mediated inflammatory skin diseases may represent a new therapeutic modality for this disease. Efalizumab is a humanized monoclonal anti-CD11a antibody that inhibits T-cell activation and migration. We report a case of a 19-year-old man suffering from AA partim universalis, treated with efalizumab monotherapy. The treatment was well tolerated with no reported side effects. The striking improvement warrants further studies with this biologic therapy in AA.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Braathen, Lasse Roger and Yawalkar, Nikhil

ISSN:

0190-9622

ISBN:

16908369

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:46

Last Modified:

04 May 2014 23:13

Publisher DOI:

10.1016/j.jaad.2006.05.062

PubMed ID:

16908369

Web of Science ID:

000240040200029

URI:

https://boris.unibe.ch/id/eprint/18893 (FactScience: 1161)

Actions (login required)

Edit item Edit item
Provide Feedback